指南与共识肾癌与肾肿瘤

欧洲泌尿外科学会指南更新:转移性透明细胞肾癌一线治疗推荐

Updated European Association of Urology Guidelines: Recommendations for the Treatment of First-line Metastatic Clear Cell Renal Cancer.
指南 / 共识 · Eur Urol · 2017-12-07

基于III期CheckMate-214试验结果,欧洲泌尿外科学会肾癌指南更新了转移性透明细胞肾癌一线治疗推荐。该试验显示伊匹木单抗联合纳武利尤单抗较既往标准治疗在中危和低危患者中生存更优。当该联合方案不安全或不可行时,应考虑舒尼替尼、帕唑帕尼和卡博替尼;在预后良好患者中数据尚不成熟,舒尼替尼或帕唑帕尼仍是首选。

要点

  • CheckMate-214显示伊匹木单抗联合纳武利尤单抗在中危和低危转移性透明细胞肾癌患者中生存优于既往标准治疗。
  • 当伊匹木单抗联合纳武利尤单抗不安全或不可行时,应考虑舒尼替尼、帕唑帕尼和卡博替尼。
  • 在预后良好患者中试验数据尚不成熟,舒尼替尼或帕唑帕尼仍是该亚组的首选药物。

核心结论

  • CheckMate-214试验结果改变了转移性透明细胞肾癌的一线标准治疗,欧洲泌尿外科学会肾癌指南据此更新。

研究设计与样本

  • 欧洲泌尿外科学会肾癌指南基于随机III期CheckMate-214临床试验结果进行更新。

主要发现

  • CheckMate-214显示伊匹木单抗联合纳武利尤单抗较既往标准治疗在中危和低危转移性透明细胞肾癌患者中生存更优。
  • 在预后良好患者中,该试验数据尚不成熟。

关键数值与推荐

  • 当伊匹木单抗联合纳武利尤单抗不安全或不可行时,应考虑舒尼替尼、帕唑帕尼和卡博替尼。
  • 在预后良好患者中,舒尼替尼或帕唑帕尼仍是首选药物。

临床怎么用

  • 原文未据此给出除上述推荐外的临床用法。

局限性

  • 在预后良好患者中,CheckMate-214试验数据尚不成熟。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The randomised phase III clinical trial Checkmate-214 showed a survival superiority for the combination of ipilimumab and nivolumab when compared with the previous standard of care in first-line metastatic/advanced clear cell renal cell carcinoma (RCC) (Escudier B, Tannir NM, McDermott DF, et al. CheckMate 214: efficacy and safety of nivolumab plus ipilimumab vs sunitinib for treatment-naïve advanced or metastatic renal cell carcinoma, including IMDC risk and PD-L1 expression subgroups. LBA5, ESMO 2017, 2017). These results change the frontline standard of care for this disease and have implications for the selection of subsequent therapies. For this reason the European Association of Urology RCC guidelines have been updated. PATIENT SUMMARY: The European Association of Urology guidelines will be updated based on the results of the phase III Checkmate-214 clinical trial. The trial showed superior survival for a combination of ipilimumab and nivolumab (IN), compared with the previous standard of care, in intermediate- and poor-risk patients with metastatic clear cell renal cell carcinoma. When IN is not safe or feasible, alternative agents such as sunitinib, pazopanib, and cabozantinib should be considered. Furthermore, at present, the data from the trial are immature in favourable-risk patients. Therefore, sunitinib or pazopanib remains the favoured agent for this subgroup of patients.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Powles T, Albiges L, Staehler M, et al. Updated European Association of Urology Guidelines: Recommendations for the Treatment of First-line Metastatic Clear Cell Renal Cancer. Eur Urol. 2017. PMID: 29223605. doi:10.1016/j.eururo.2017.11.016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。